OptiBiotix Health (OPTI) Share Price, News & Analysis

Company Overview

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Key Stats

• Today's Range: 5.50 to 6
• 50-Day Range: 5.50 to 6.50
• 52-Week Range: 4.50 to 13.50
• Volume: 100,549 shs
• Average Volume: 383,466 shs
• Market Capitalization: £5.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/28/2026
• Today: 8/01/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: LON:OPTI
• Previous Symbol: LON:CMI
• CIK: N/A
• Web: www.optibiotix.com
• Phone: +44-20-79338780
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (3.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£3.09 million
• Net Margins: -333.62%
• Pretax Margin: N/A
• Return on Equity: -52.92%
• Return on Assets: -13.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.27
• Quick Ratio: 7.89

Sales & Book Value

• Annual Sales: £1.17 million
• Price / Sales: 4.87
• Cash Flow: GBX 0.63 per share
• Price / Cash Flow: 8.68
• Book Value: GBX 7.80 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 103,300,000
• Free Float: N/A
• Market Cap: £5.68 million
• Optionable: Not Optionable
• Beta: 1.85